Regulation
Rules, guidance and how the agencies work.
Stories
-
FDA requests nominations for voting members of advisory committees
The agency is seeking qualified individuals to fill scientific, technical, professional, and other voting-member positions. The notice was published October 1, 2026.
-
FDA requests nominations for consumer representatives on advisory committees
The FDA is requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. Nominations will be accepted for current vacancies and for those that will or may occur through December 31, 2026, with interest letters due by November 16, 2026.
-
FDA determines ISTURISA not withdrawn from sale
The FDA has determined that ISTURISA (osilodrostat) tablets, 10 mg, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications for osilodrostat tablets, 10 mg if all other legal and regulatory requirements are met.
-
EMA endorses ICMRA joint statement on animal testing alternatives
EMA has endorsed a joint statement from the International Coalition of Medicines Regulatory Authorities (ICMRA) calling on medicine developers, manufacturers, regulators and national control laboratories to advance alternative methods to animal testing throughout the medicine lifecycle. The statement sets a long-term goal of replacing animal testing at all stages, from initial candidate screening to post-authorization activities.
-
EMA sets end-of-year submission dates for type I variations in 2026
EMA advises marketing authorization holders to submit type IA annual updates, individual type IA and type IA IN variations, and super-groupings no later than 20 November 2026. Submissions received after 20 November will still be processed, but the outcome may not be issued until January 2027.
-
PRAC carries out safety assessment duties at its 28 September - 1 October meeting
The Pharmacovigilance Risk Assessment Committee (PRAC) reviewed 9 safety signals, 85 periodic safety update reports, 49 risk management plans and 16 post-authorization safety studies. No referral procedures were started, ongoing or concluded during the meeting.
-
FDA classifies flushing and storage solution for vascular autografts at room temperature as class II
The order places the device type into class II (special controls), which the FDA has determined will provide a reasonable assurance of the safety and effectiveness of the device. The FDA said the action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
-
FDA rewrites drug safety rules to say “nonclinical,” not “animal,” testing
A direct final rule takes effect February 4, 2027, unless the agency receives significant adverse comments by December 7, 2026.